Medicare Enrolled
Dr. Vijaykumar Roy, MD
Hematology & Oncology · Wayne, NJ
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Roy from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Roy?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Roy
Dr. Vijaykumar Roy is a hematology & oncology specialist in Wayne, NJ, with 20 years of NPI registration. Based on federal Medicare data, Dr. Roy performed 77,387 Medicare services across 1,292 unique beneficiaries.
Between the years covered by Open Payments, Dr. Roy received a total of $15,255 from 68 pharmaceutical and/or device companies across 541 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Roy is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 14% volume in NJ
$15,255 industry payments
Medicare Practice Summary
Medicare Utilization ↗77,387
Medicare services
Top 14% in NJ for hematology & oncology
1,292
Unique beneficiaries
$6
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~3,869 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
39,000 | $1 | $2 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
15,800 | $6 | $20 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
10,220 | $6 | $20 |
| Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 2,951 | $2 | $10 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,898 | $0 | $3 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
1,837 | $8 | $10 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,815 | $8 | $38 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,420 | $74 | $150 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
714 | $12 | $35 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
379 | $58 | $100 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
316 | $109 | $200 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
305 | $26 | $60 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
283 | $120 | $225 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
223 | $14 | $35 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
126 | $26 | $60 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
100 | $133 | $200 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
51.6% high complexity
41.3% medium
7.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$15,255
Total received (2018-2024)
Avg $2,179/year across 7 years
Top 18% in NJ for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
68
Companies
541
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$11,388 (74.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$2,062 (13.5%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,805 (11.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,438
2023
$2,203
2022
$796
2021
$1,511
2020
$580
2019
$4,268
2018
$2,460
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$686
Janssen Biotech, Inc.
$523
Incyte Corporation
$250
Astellas Pharma US Inc
$235
AstraZeneca Pharmaceuticals LP
$232
BeiGene USA, Inc.
$220
PharmaEssentia USA Corporation
$206
Celgene Corporation
$190
PFIZER INC.
$139
GENZYME CORPORATION
$133
Bayer Healthcare Pharmaceuticals Inc.
$88
SANOFI-AVENTIS U.S. LLC
$85
TAIHO ONCOLOGY, INC.
$68
Merck Sharp & Dohme LLC
$67
ABBVIE INC.
$46
Gilead Sciences, Inc.
$38
Mirati Therapeutics, Inc.
$36
Aveo Pharmaceuticals, Inc.
$31
Novartis Pharmaceuticals Corporation
$26
Adaptive Biotechnologies Corporation
$25
SHIELD THERAPEUTICS INC
$23
GlaxoSmithKline, LLC.
$23
Takeda Pharmaceuticals U.S.A., Inc.
$21
Biocon Biologics Inc
$18
Legend Biotech USA Inc.
$15
Daiichi Sankyo Inc.
$15
Top 3 companies account for 42.4% of 2024 payments
All-time payments by company (2018-2024) ›
Janssen Biotech, Inc.
$2,711
E.R. Squibb & Sons, L.L.C.
$2,104
AstraZeneca Pharmaceuticals LP
$1,086
Incyte Corporation
$1,017
Celgene Corporation
$739
Amgen Inc.
$661
Astellas Pharma US Inc
$578
PFIZER INC.
$535
GENZYME CORPORATION
$469
Novartis Pharmaceuticals Corporation
$447
Coherus Biosciences Inc.
$265
BeiGene USA, Inc.
$241
Daiichi Sankyo Inc.
$229
Medtronic Vascular, Inc.
$220
PharmaEssentia USA Corporation
$206
Seagen Inc.
$204
Regeneron Healthcare Solutions, Inc.
$194
Bayer Healthcare Pharmaceuticals Inc.
$184
Seattle Genetics, Inc.
$182
Genentech USA, Inc.
$181
Merck Sharp & Dohme Corporation
$178
Kite Pharma, Inc.
$171
SANOFI-AVENTIS U.S. LLC
$170
Bayer HealthCare Pharmaceuticals Inc.
$164
Boston Scientific Corporation
$150
Gilead Sciences, Inc.
$136
Merck Sharp & Dohme LLC
$135
GlaxoSmithKline, LLC.
$132
Lilly USA, LLC
$129
BIOTRONIK INC.
$118
Progenics Pharmaceuticals, Inc.
$108
Takeda Pharmaceuticals U.S.A., Inc.
$94
Pharmacyclics LLC, An AbbVie Company
$76
TAIHO ONCOLOGY, INC.
$68
Celltrion USA Inc.
$66
Mirati Therapeutics, Inc.
$50
Heron Therapeutics, Inc.
$49
ABBVIE INC.
$46
Foundation Medicine, Inc.
$45
TESARO, Inc.
$43
AbbVie, Inc.
$42
Otsuka America Pharmaceutical, Inc.
$41
Teva Pharmaceuticals USA, Inc.
$40
Alexion Pharmaceuticals, Inc.
$40
Genentech, Inc.
$38
Aveo Pharmaceuticals, Inc.
$31
Eisai Inc.
$30
Boehringer Ingelheim Pharmaceuticals, Inc.
$29
EISAI INC.
$28
Spectrum Pharmaceuticals Inc.
$28
Rigel Pharmaceuticals, Inc.
$28
Dendreon Pharmaceuticals LLC
$26
Adaptive Biotechnologies Corporation
$25
SHIELD THERAPEUTICS INC
$23
Deciphera Pharmaceuticals Inc.
$23
Pharmacosmos Therapeutics Inc.
$21
Octapharma USA, Inc.
$20
Blueprint Medicines Corporation
$19
Biocon Biologics Inc
$18
Karyopharm Therapeutics Inc.
$15
AMAG Pharmaceuticals, Inc.
$15
TerSera Therapeutics LLC
$15
Legend Biotech USA Inc.
$15
MEDIVATION FIELD SOLUTIONS LLC
$14
ImmunoGen, Inc.
$14
EMD Serono, Inc.
$13
Mylan Institutional Inc.
$12
Lexicon Pharmaceuticals, Inc.
$12
Top 3 companies account for 38.7% of all-time payments
Associated products mentioned in payments ›
ACCRUFER · ADCETRIS · ALIMTA · AYVAKIT · Abraxane · Alecensa · Aliqopa · Aranesp · Avastin · BESREMI · BLENREP · BOSULIF · BRUKINSA · Beleodaq · Blincyto · CALQUENCE · CAMZYOS · CINVANTI · CYRAMZA · CardioInsight · DARZALEX · ELIQUIS · ELITEK · ENHERTU · EPKINLY · ERBITUX · ERLEADA · Elahere · Enhertu · Erleada · FASLODEX · FERAHEME · FOTIVDA · GAZYVA · GILOTRIF · Halaven · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · JADENU · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LUPRON DEPOT · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MONOFERRIC · MVASI · MYLOTARG · NINLARO · Neulasta · Nexavar · Nplate · Nubeqa · OJJAARA · OPDIVO · OPDUALAG · OXBRYTA · Ogivri · PADCEV · PROMACTA · PROVENGE · PYLARIFY · Padcev · Pomalyst · QINLOCK · REBLOZYL · RYBREVANT · RYDAPT · Revlimid · SARCLISA · SCEMBLIX · SOLIRIS · SPRYCEL · SUTENT · Stivarga · TAGRISSO · TECENTRIQ · TECVAYLI · TREANDA · Tavalisse · Turalio · ULTOMIRIS · Udenyca · VEGZELMA · Venclexta · Viva · WATCHMAN FLX · WELIREG · WILATE · XALKORI · XOSPATA · XPOVIO · XTANDI · Xermelo · Xofigo · Xtandi · Yescarta · ZEJULA · ZOLADEX · ZYTIGA · Zevalin · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (75%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
566
Per 100K population
109.2
County median income
$87,137
Nearest hospital
CHILTON MEDICAL CENTER
3.6 mi
3.6 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Roy is a mixed practice specialist, with above-average Medicare volume (top 14% in NJ), with low-engagement industry engagement in the top 18% of NJ peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Roy experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Roy performed 39,000 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Roy receive payments from pharmaceutical companies?
Yes. Dr. Roy received a total of $15,255 from 68 companies across 541 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Roy's costs compare to other hematology & oncology specialists in Wayne?
Dr. Roy's average Medicare payment per service is $6. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Roy) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Wayne
Browse hematology & oncology specialists in Wayne ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in NJ
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in NJ
Which NJ hematology & oncology specialists receive the most from drug and device companies.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology